Datasheet

DEPDC1B Antibody
CATALOG NUMBER: 8283

Availability: In stock

$0.00
Product Price Options

* Required Fields

$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human
HOMOLOGY:Predicted species reactivity based on immunogen sequence: Mouse: (94%), Chicken: (88%)
TESTED APPLICATIONS:ELISA, IHC-P, WB
APPLICATIONS:DEPDC1B antibody can be used for detection of DEPDC1B by Western blot at 1 - 2 μg/ml. Antibody can also be used for immunohistochemistry starting at 5 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1204 - K562 Cell Lysate
 2) Cat. No. 10-901 - Human Spleen Tissue Slide
PREDICTED MOLECULAR WEIGHT:Predicted: 58 kDa

Observed: 57 kDa
SPECIFICITY:DEPDC1B antibody is human specific. At least two isoforms are known to exist; this antibody will only detect the largest isoform. DEPDC1B antibody is predicted to not cross-react with DEPDC1A.
IMMUNOGEN:DEPDC1B antibody was raised against a 19 amino acid peptide near the carboxy terminus of human DEPDC1B.

The immunogen is located within the last 50 amino acids of DEPDC1B.
HOST SPECIES:Rabbit

Properties

PURIFICATION:DEPDC1B antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:DEPDC1B antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:DEPDC1B antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:DEP domain-containing 1B, DEP1B, BRCC3, Breast cancer cell 3, XTP1
ACCESSION NO.:NP_060839
PROTEIN GI NO.:223633999
OFFICIAL SYMBOL:DEPDC1B
GENE ID:55789

Background

BACKGROUND:The DEP domain-containing 1B (DEPDC1B) protein was initially identified as a radiation response biomarker in human lymphoblastoid cell lines (1). Like the related protein DEPDC1A, expression of DEPDC1B correlates with a poor prognosis in cancer patients (2,3). Studies have shown that DEPDC1B levels are upregulated in non-small cell lung cancer (NSCLC) and have an inverse correlation with patient survival. Ectopic expression of DEPDC1B in NSCLC activated Wnt/B-catenin signaling and enhanced cell migration and invasion while silencing DEPDC1B expression suppressed these traits (2).
REFERENCES: 1) Niu N, Qin Y, Fridley BL, et al. Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res. 2010; 20:1482-92.
2) Yang Y, Liu L, Cai J, et al. DEPDC1B enhances migration and invasion of non-small cell lung cancer cells via activating Wnt/B-catenin signaling. Biochem. Biophys. Res. Commun. 2014; 450:899-905.
3) Kassambara A, Schoenhals M, Moreaux J, et al. Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells. PLoS One 2013; 8:e62752.

For Research Use Only